- Kristi Powers
Choose the health content that’s right for you, and get it delivered right in your inbox.
AdventHealth physician says it could lead to more treatment options for kidney patients and others

New research, conducted in part at AdventHealth, shows medicines like Ozempic can dramatically reduce the risk of serious illness in people with kidney disease.
“In the near future, this treatment could become one of the pillars of therapy for patients with Type 2 diabetes (T2D) and chronic kidney disease because of the powerful effects this study shows, not just on kidney progression, but on heart disease and mortality,” said Dr. Richard E. Pratley, senior investigator at the AdventHealth Translational Research Institute. “This treatment positively affects multiple organs to decrease risk and this study confirms it’s a whole body, holistic type of treatment. It’s not just a medication focused on lowering blood sugar; it has other major benefits.”
Pratley believes this research supports Ozempic as a life-saving option for a new set of patients. He is the senior author on a recently published study in the New England Journal of Medicine (NEJM) article which looks at the effects of Ozempic in persons with Type 2 diabetes patients with chronic kidney disease.
The trial, called FLOW, evaluated the efficacy and safety of semaglutide (Ozempic) given once weekly in people with T2D and chronic kidney disease from preventing:
- Kidney failure
- Substantial loss of kidney function
- Death from kidney or cardiovascular causes
The groundbreaking study results show promising outcomes and Pratley is confident it will quickly obtain FDA approval, making Ozempic a life-saving option for a new set of patients for whom additional treatment options are badly needed.
“This research shows us where Ozempic’s strengths lie,” Pratley said. “Ozempic has demonstrated efficacy with many of the important complications associated with type 2 diabetes, including heart and kidney disease.”
The study results of over 3,500 participants who were followed for an average of 3.4 years showed:
- 24% lower risk of kidney events worsening kidney function, transplant dialysis, kidney death and cardiovascular disease
- 18% lower risk of major cardiovascular events (heart attack, stroke, etc.)
- 20% lower risk of death
“By sharing these insights with other physicians and clinicians through the NEJM, we hope our findings will eventually become the standard of whole person care globally to improve patient outcomes.”
This is the first study of its kind to examine a GLP-1 receptor agonist (semaglutide) and its effects on kidney outcomes and with promising results, Pratley hopes to drive change in screening for kidney disease.
“There’s a big gap in the number of patients who have kidney disease and the number who are diagnosed,” said Pratley. “Screening needs to start happening with the primary care physician to identify kidney disease in its early stages because we now have treatments that can prevent disease progression.”
In addition to these new findings, there are also other potential benefits of Ozempic being explored, such as improving heart failure in patients and even secondary benefits like improving liver disease and sleep apnea.
Recent News
More than 100 local leaders, clinicians and community partners gathered recently for AdventHealth Daytona Beach’s first State of the Hospital address for a look at how the hospital is evolving to meet...
Get With The Guidelines® is the American Heart Association/American Stroke Association’s hospital-based quality improvement program that provides hospitals with the latest research-based guidelines.
Urinary leakage is a challenge many athletes face—often during or after exercise—due to the stress placed on the pelvic floor through strenuous or repetitive movements. Lisa Zwiers, PA-C, with...
Acetaminophen, commonly known by the brand name Tylenol, has been a staple in medicine cabinets since its clinical introduction in 1955.
This heartwarming reunion and the success of this case underscore the impact of early symptom recognition, coordinated EMS response, and hospital readiness.
AdventHealth is celebrating the winners of the latest AdventHealth Pinnacle Physician Award, Charles Morlok, MD, and the inaugural AdventHealth Pinnacle APP Award, Sarah Ducker, MSN, FNP-C, AOCNP...
Six hospitals in Florida are the latest AdventHealth facilities to earn national accreditation for their nurse residency program – a recognition that affirms their commitment to developing and...
When a doctor steps into the room with a patient, it’s often right to business. But Dr. Jayson Sack at AdventHealth Wesley Chapel has found a way to connect on a more friend-like level.
AdventHealth Waterman achieves milestone in robotic cardiac surgery.
AdventHealth Waterman achieves milestone in robotic cardiac surgery with the da Vinci robot. The procedure, called a bilateral internal mammary artery minimally invasive direct coronary artery bypass...
AdventHealth Gordon is proud to announce that Derek Shawgo, RN, has been honored with the DAISY Award for Extraordinary Nurses.
Lake Mary Little League®, home of the 2024 Little League® World Series Champions, is proud to announce a new partnership with AdventHealth.